Trial Profile
A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naive MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Lesinidase alfa (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions
- Acronyms CL01-T
- Sponsors Alexion AstraZeneca Rare Disease; Synageva BioPharma
- 19 Apr 2018 Status changed from active, no longer recruiting to discontinued.
- 03 Feb 2016 According to an Alexion Pharmaceuticals media release, Six-month data will be presented as a late-breaker abstract at the WORLDSymposium 2016 meeting.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.